Navigation Links
Oppenheimer's Investment Bank Continues Expansion -- Lance Alstodt Named Managing Director - Healthcare
Date:10/7/2009

NEW YORK, Oct. 7 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings, is pleased to announce that Lance Alstodt will join the firm as Managing Director in Healthcare in the firm's burgeoning Investment Banking area. He will report to Brian McCarthy, Oppenheimer's Head of Healthcare Investment & Corporate Banking.

"Lance is an experienced and very capable senior banker in the medical technology space. He will be a real driver of our medical technology effort and is an important addition to the firm," said Brian McCarthy.

Lance joins Oppenheimer from Bank of America Merrill Lynch, where he worked in both the Global Mergers & Acquisitions and Global Healthcare Investment Banking Groups, generating and executing financing and advisory transactions in the Medical Technology sector.

Before moving to Bank of America Merrill Lynch, Lance had worked in the Global Mergers and Acquisitions Group at JP Morgan Chase, with a focus on Healthcare.

"Medical technology is an important piece of our Healthcare investment banking practice and we view Lance as a highly strategic hire and we're delighted he has joined us," said Marshall Heinberg, Oppenheimer's Head of Investment & Corporate Banking.

Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), provides a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.

SOURCE Oppenheimer & Co. Inc.


'/>"/>
SOURCE Oppenheimer & Co. Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
4. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
7. Cord Blood America Continues to Reduce Debt; Three Notes Retired
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. TMS Health Continues to Expand - Adding Over 60 New Jobs at Boca Raton Headquarters
10. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
11. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):